Nelson Vergel
Founder, ExcelMale.com
“The FDA buckled to pressure from a savvy astroturf campaign and approved Addyi despite serious health risks and negligible benefits,” said Cindy Pearson, Executive Director. “Looking back one year later, we see a lot of broken promises, studies that were never conducted, safety training that's laughably bad. Once again it's clear: all women would be wise to pass on the pink pill.”
In 2015, the NWHN launched an awareness campaign, “Pass on the Pink Pill –or Pass out” warning women to avoid the drug due to its dangerous side effects and low effectiveness. The manufacturer's own clinical trials have shown that Addyi doesn't work for 9 out of 10 women, and barely works at all, for the other 10 percent. Now, amidst poor sales reflecting its limited benefit to women, advocates expect an expensive and misleading direct-to-consumer ad campaign to boost sales may be coming soon.
Learn more about the advocacy work NWHN has been doing on this issue – Pass on the Pink Pill – Or Pass Out! | National Women's Health Network.
- See more at: Health Advocates Issue One-Year Report Card on Addyi, the Female Libido Drug | National Women's Health Network
In 2015, the NWHN launched an awareness campaign, “Pass on the Pink Pill –or Pass out” warning women to avoid the drug due to its dangerous side effects and low effectiveness. The manufacturer's own clinical trials have shown that Addyi doesn't work for 9 out of 10 women, and barely works at all, for the other 10 percent. Now, amidst poor sales reflecting its limited benefit to women, advocates expect an expensive and misleading direct-to-consumer ad campaign to boost sales may be coming soon.
Learn more about the advocacy work NWHN has been doing on this issue – Pass on the Pink Pill – Or Pass Out! | National Women's Health Network.
- See more at: Health Advocates Issue One-Year Report Card on Addyi, the Female Libido Drug | National Women's Health Network
